These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8549407)

  • 21. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review.
    Goldstein MH; Kowalski RP; Gordon YJ
    Ophthalmology; 1999 Jul; 106(7):1313-8. PubMed ID: 10406613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of experimental bacterial keratitis with topical trovafloxacin.
    Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
    Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN; Pfaller MA
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.
    Gargallo-Viola D; Ferrer S; Tudela E; Robert M; Coll R; Roser R; Guinea J
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3113-21. PubMed ID: 11600365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers.
    Diekema DJ; Jones RN; Rolston KV
    Diagn Microbiol Infect Dis; 1999 May; 34(1):37-43. PubMed ID: 10342106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.
    Eliopoulos GM; Klimm K; Eliopoulos CT; Ferraro MJ; Moellering RC
    Antimicrob Agents Chemother; 1993 Feb; 37(2):366-70. PubMed ID: 8452372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolones.
    O'Donnell JA; Gelone SP
    Infect Dis Clin North Am; 2000 Jun; 14(2):489-513, xi. PubMed ID: 10829268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.
    Neu HC
    Drugs; 1993; 45 Suppl 3():54-8. PubMed ID: 7689452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the fluoroquinolones on gastrointestinal flora.
    Korten V; Murray BE
    Drugs; 1993; 45 Suppl 3():125-33. PubMed ID: 7689443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoroquinolone resistance among Gram-positive cocci.
    Hooper DC
    Lancet Infect Dis; 2002 Sep; 2(9):530-8. PubMed ID: 12206969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The fluoroquinolones: how long will their utility last?
    Bakken JS
    Scand J Infect Dis; 2004; 36(2):85-92. PubMed ID: 15061660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.
    Stein GE
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S19-24. PubMed ID: 8953102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.
    Poole K
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2595-9. PubMed ID: 10991829
    [No Abstract]   [Full Text] [Related]  

  • 39. Activity of CI-934 against gram-positive bacteria.
    Rolston KV; Bodey GP
    J Antimicrob Chemother; 1986 Dec; 18(6):768-9. PubMed ID: 3818499
    [No Abstract]   [Full Text] [Related]  

  • 40. Perspectives on newer oral antimicrobials: what do they add?
    Harrison CJ
    Pediatr Infect Dis J; 1995 May; 14(5):436-44. PubMed ID: 7638034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.